439 related articles for article (PubMed ID: 15728298)
1. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.
Sándor PS; Di Clemente L; Coppola G; Saenger U; Fumal A; Magis D; Seidel L; Agosti RM; Schoenen J
Neurology; 2005 Feb; 64(4):713-5. PubMed ID: 15728298
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine.
Slater SK; Nelson TD; Kabbouche MA; LeCates SL; Horn P; Segers A; Manning P; Powers SW; Hershey AD
Cephalalgia; 2011 Jun; 31(8):897-905. PubMed ID: 21586650
[TBL] [Abstract][Full Text] [Related]
3. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis.
Magis D; Ambrosini A; Sándor P; Jacquy J; Laloux P; Schoenen J
Headache; 2007 Jan; 47(1):52-7. PubMed ID: 17355494
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.
Cady RK; Mathew N; Diener HC; Hu P; Haas M; Novak GP;
Headache; 2009 Feb; 49(2):216-26. PubMed ID: 19222595
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.
Goadsby PJ; Ferrari MD; Csanyi A; Olesen J; Mills JG;
Cephalalgia; 2009 Jul; 29(7):742-50. PubMed ID: 19222510
[TBL] [Abstract][Full Text] [Related]
9. Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis.
Bianchi A; Salomone S; Caraci F; Pizza V; Bernardini R; D'Amato CC
Vitam Horm; 2004; 69():297-312. PubMed ID: 15196887
[TBL] [Abstract][Full Text] [Related]
10. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine.
Hershey AD; Powers SW; Vockell AL; Lecates SL; Ellinor PL; Segers A; Burdine D; Manning P; Kabbouche MA
Headache; 2007 Jan; 47(1):73-80. PubMed ID: 17355497
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
13. Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial.
Saper J; Dahlof C; So Y; Tfelt-Hansen P; Malbecq W; Loeys T; Barraclough E; Klipfel M; Lines C; Visser H; Reines S; Yuen E;
Headache; 2006 Feb; 46(2):264-75. PubMed ID: 16492236
[TBL] [Abstract][Full Text] [Related]
14. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
Relja M; Poole AC; Schoenen J; Pascual J; Lei X; Thompson C;
Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
[TBL] [Abstract][Full Text] [Related]
15. Acupuncture in migraine prevention: a randomized sham controlled study with 6-months posttreatment follow-up.
Alecrim-Andrade J; Maciel-Júnior JA; Carnè X; Severino Vasconcelos GM; Correa-Filho HR
Clin J Pain; 2008 Feb; 24(2):98-105. PubMed ID: 18209514
[TBL] [Abstract][Full Text] [Related]
16. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial.
Donaldson D; Sundermann R; Jackson R; Bastani A
Am J Emerg Med; 2008 Feb; 26(2):124-30. PubMed ID: 18272089
[TBL] [Abstract][Full Text] [Related]
17. The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial.
Parohan M; Sarraf P; Javanbakht MH; Foroushani AR; Ranji-Burachaloo S; Djalali M
Nutr Neurosci; 2021 Apr; 24(4):317-326. PubMed ID: 31241007
[No Abstract] [Full Text] [Related]
18. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M
Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
[TBL] [Abstract][Full Text] [Related]
19. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
Diener HC; Gendolla A; Gebert I; Beneke M
Headache; 2005; 45(7):874-82. PubMed ID: 15985104
[TBL] [Abstract][Full Text] [Related]
20. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
